KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

被引：2
|
作者：
Salvatore, L. [1 ]
Loupakis, F. [1 ]
Fontanini, G. [2 ]
Cremolini, C. [1 ]
Stasi, I. [3 ]
Fabbri, A. [4 ]
Ciarlo, A. [5 ]
Granetto, C. [6 ]
Basolo, F. [2 ]
Falcone, A. [7 ]
机构：
[1] Univ Pisana, Azienda Osped, UO Oncol Med Univ 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ Pisana, Azienda Osped, UO Anat Patol Sperimentale Univ, Pisa, Italy
[3] Azienda USL 6, UO Oncol Med, Ist Toscano Tumori, Livorno, Italy
[4] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol Oncol Med, Rome, Italy
[5] Osped Misericordia & Dolce, UO Oncol Med, Prato, Italy
[6] Osped S Croce & Carle, UO ONcol Med, Cuneo, Italy
[7] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, Pisa, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71155-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [1] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [2] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [3] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [5] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [7] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [8] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [9] FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
    Damato, Angela
    Bergamo, Francesca
    Antonuzzo, Lorenzo
    Nasti, Guglielmo
    Iachetta, Francesco
    Romagnani, Alessandra
    Gervasi, Erika
    Larocca, Mario
    Pinto, Carmine
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345